Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04128007 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
A Phase 2 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 304
- Enrollment target
NCT04128007 is a Phase 2 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 304 participants.
The verdict
NCT04128007, a Phase 2 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 304 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis
Interventions
- DRUG Vehicle foam
- DRUG Roflumilast foam 0.3%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2020-09-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04128007
The ClinicalTrials.gov registry entry for NCT04128007 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle foam is the first listed.
NCT04128007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04128007 about?
NCT04128007 is a clinical study titled "Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis". This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis
What is the current status of trial NCT04128007?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 304 participants. The study started on 2020-01-13. Estimated completion is 2020-09-25.
What interventions are being tested in trial NCT04128007?
The interventions under investigation include: Vehicle foam (DRUG), Roflumilast foam 0.3% (DRUG).
Who is sponsoring clinical trial NCT04128007?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.